Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P467

Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids

Authors:

N. Narula*1, J. Marshall2, J.-F. Colombel1, G.I. Leontiadis2, Z. Maqtadir2, W. Reinisch2

1Mount Sinai Hospital, Gastroenterology, New York, United States, 2McMaster University, Gastroenterology, Hamilton, Canada

P468.

Hospitalization rate before and after anti-TNF therapy, results from two referral centers

Authors:

P.A. Golovics1, A. Balint2, M. Mandel1, Z. Vegh1, A. Mohas1, B. Szilagyi1, A. Szabo1, Z. Kurti1, L. Kiss1, B. Lovasz1, K. Farkas2, T. Molnar2, P. Lakatos1, 1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2University of Szeged, 1st Department of Medicine, Szeged, Hungary

P468. Incidence rate of lymphoma by the cumulative duration of exposure to thiopurines: a nationwide retrospective cohort from the Veterans Affairs healthcare system
Authors:

A. Abbas1, Y. Koleva2, N. Khan2, 1Tulane University, Gastroenterology, New Orleans, United States, 2Southeast Louisiana Veterans Health Care System, Gastroenterology, New Orleans, United States

P468. Screening using the ECCO guidelines demonstrates high strongyloides sero-prevalence in migrants with inflammatory bowel disease
P468

Appendectomy is associated with an increased risk of colonic neoplasia in Ulcerative Colitis

Authors:

Y. Harnoy*1, Y. Bouhnik2, V. Desfourneaux1, L. Maggiori3, L. Sulpice1, B. Larroque4, D. Cazals-Hatem5, K. Boudjema1, Y. Panis3, E. Ogier-Denis6, X. Treton2

1Hopital Pontchaillou, CHU de Rennes, Service de Chirurgie Hépatobiliaire et Digestive, SCHBD, Rennes, France, 2Hôpital Beaujon, Gastroentérologie, MICI et Assistance Nutritive, Clichy, France, 3Université Paris Diderot Hôpital Beaujon - APHP, Service de Chirurgie Colo-rectale, Clichy, France, 4Université Paris Diderot Hôpital Beaujon - APHP, Département de la recherche Clinique, Clichy, France, 5Université Paris Diderot Hôpital Beaujon - APHP, Département d'anatomopathologie, Clichy, France, 6INSERM, UMRS1149, Team «Physiopathology of Inflammatory Bowel Diseases», Centre de Recherche Bichat Beaujon, Paris, France

P469.

Higher red blood cell methotrexate polyglutamates correlate with increased disease activity, and are useful in assessing adherence

Authors:

S. Fong1, M.G. Ward1, I. Nasr1, R.M. Goel1, K.V. Patel1, S. Ray1, M. Arenas Hernandez2, S.A. Anderson1, T. Marinaki2, J.D. Sanderson1, P.M. Irving1, 1Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Purine Research Laboratory, GSTS Pathology, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom

P469. Influence of bodyweight on response to adalimumab treatment in patients with Crohn's disease
Authors:

E. Leo Carnerero1, J.M. Alcivar Vasquez1, C. Trigo Salado1, D. De la Cruz Ramírez1, F. Domínguez Abascal1, J.M. Herrera Justiniano1, J.L. Márquez Galán1, 1HU Virgen del Rocío, Digestive diseases, Seville, Spain

P469

Accelerated treatment strategy in Inflammatory Bowel Diseases: Is it associated with a change in the disease course?

Authors:

L. Kiss1, K. Farkas2, N. Sipeki3, Z. Kurti1, P.A. Golovics1, M. Rutka2, 4, B. Lovasz1, Z. Vegh1, K. Gecse1, I. Altorjay3, M. Papp3, T. Molnar2, P. Lakatos*1

1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2University of Szeged, 1st Department of Medicine, Szeged, Hungary, 3University of Debrecen, Institute of Internal Medicine, Department of Gastroenterology, Debrecen, Hungary, 4University of Szeged, First Department of Medicine, Szeged, Hungary

P470.

High infliximab trough levels are associated with impaired quality of life in IBD patients in clinical and biochemical remission on maintenance IFX therapy

Authors:

M. Löwenberg1,2, J. Brandse2,3, L. Vos2,3, C. Ponsioen2,3, G. van den Brink2,3, G. D'Haens2,3, 1Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands, 2AMC, Gastroenterology, Amterdam, Netherlands, 3Academic Medical Center Amsterdam, Department of Internal Medicine, Amsterdam, Netherlands

P470. Infliximab treatment for paediatric Crohn's disease: long-term outcomes at a single centre
Authors:

P. Church1, J. Guan1, K. Frost1, A. Muise1, T. Walters1, A. Griffiths1, 1Hospital for Sick Children, Paediatrics, Toronto, Canada

P470

Changes in serum through levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease

Authors:

C. Steenholdt*1, K. Bendtzen2, J. Brynskov1, O.Ø. Thomsen1, L.K. Munck3, L.A. Christensen4, G. Pedersen5, J. Kjeldsen6, M.A. Ainsworth1

1Herlev Hospital, Dept of Gastroenterology, Herlev, Denmark, 2Rigshospitalet, University Hospital of Copenhagen, Institute for Inflammation Research, Copenhagen, Denmark, 3Køge Hospital, Dept. of Medical Gastroenterology, Køge, Denmark, 4Aarhus Hospital, Dept. of Hepatology and Gastroenterology V, Aarhus, Denmark, 5Hvidovre Hospital, Dept. of Gastroenterology, Hvidovre, Denmark, 6Odense Hospital, Dept. of Medical Gastroenterology S, Odense, Denmark

P471.

Hematopoietic stem cell transplantation in refractory Crohn's disease: Feasibility and toxicity

Authors:

A. Jauregui-Amezaga1, M. Rovira2, S. Pinó Donnay1, P.J. Marín2, F. Feu1, J.I. Elizalde1, F. Fernández-Avilés2, C. Martínez2, L. Rosiñol2, M. Suarez-Lledó2, M.C. Masamunt1, A. Ramírez-Morros1, M. Gallego1, I. Ordás1, J. Panés1, E. Ricart1, 1Hospital Clínic de Barcelona, Gastroenterology Department, Barcelona, Spain, 2Hospital Clínic de Barcelona, Hematology Department, Barcelona, Spain

P471. Infliximab therapy in patients with chronic refractory pouchitis: efficacy and safety
Authors:

A. Indriolo1, L. Campanati2, L. Ansaloni2, F. Caprioli3, E. Contessini Avesani4, P. Ravelli1, 1Ospedali Riuniti di Bergamo, Gastroenterology and Digestive Endoscopy Unit II, Bergamo, Italy, 2Ospedali Riuniti di Bergamo, Surgery I Unit, Bergamo, Italy, 3University of Milan, Department of Gastroenterology, Milan, Italy, 4University of Milan, Division II of General Surgery, Milan, Italy

P471

Infliximab trough levels are lower in patients with acute severe, compared to moderate-severe ulcerative colitis patients

Authors:

B. Ungar*1, Y. Mazor2, H. Yanai3, Y. Ron3, A. Waizbard3, M. Yavzori1, E. Fudim1, O. Picard1, R. Loebstein4, U. Kopylov1, I. Dotan3, Y. Chowers2, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Center & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel, 3Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 4Sheba Medical Center & Sackler School of Medicine, Institute of Clinical Pharmacology, Tel Hashomer, Israel

P472.

Head-to-head comparison of 5 fecal markers to predict response to induction and maintenance therapy with infliximab in ulcerative colitis patients; a prospective study

Authors:

A.C. Frin1, S. Nancey2, J. Filippi1, G. Boschetti2, B. Flourié2, J. Drai3, P. Ferrari4, X. Hebuterne1, 1Archet 2 University Hospital, Gastro enterology, Nice, France, 2Hospices Civils de Lyon, Lyon-Sud hospital, Gasroenterology, Pierre Benite, France, 3Hospices Civils de Lyon, Lyon-Sud hospital, Biochemistry, Pierre-Benite, France, 4Pasteur University Hospital, Biochemistry, Nice, France

P472. Infliximab therapy for inflammatory bowel disease in patients post liver transplatation
Authors:

A. Indriolo1, S. Fagiuoli2, L. Pasulo2, G. Fiorino3, S. Danese3, P. Ravelli1, 1Ospedali Riuniti di Bergamo, Gastroenterology and Digestive Endoscopy Unit II, Bergamo, Italy, 2Ospedali Riuniti di Bergamo, Gastroenterology I and Liver Transplantation Unit, Bergamo, Italy, 3IRCSS Umanitas, IBD Center, Gastroenterology, Rozzano, Italy

P472

Risk of relapse after anti-TNF discontinuation in Inflammatory Bowel Disease: A meta-analysis

Authors:

J.P. Gisbert*, A.C. Marín, M. Chaparro

Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain

P473.

Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab

Authors:

A. Tursi1, W. Elisei2, M. Picchio3, G. Forti4, A. Penna5, P.G. Lecca6, M. Di Fonzo6, L. Di Cesare6, G. Brandimarte6, 1Azienda Sanitaria Locale BAT, Servizio di Gastroenterologia Territoriale, Andria, Italy, 2ASL RMH, Division of Gastroenterology, Albano Laziale, Italy, 3“P. Colombo” Hospital, ASL RMH, Division of Surgery, Velletri, Italy, 4“S. Maria Goretti” Hospital, Digestive Endoscopy Unit, Latina, Italy, 5“S. Paolo” Hospital, Division of Gastroenterology, Bari, Italy, 6“Cristo Re” Hospital, Division of Gastroenterology, Rome, Italy

P473. Infliximab is more immunogenic and reaches lower trough levels in ulcerative colitis patients compared to Crohn's disease patients
Authors:

H. Bar-yoseph1, Y. Chowers1, S. Ben-Horin2, M. Waterman1, 1Rambam, Gastroenterology, Haifa, Israel, 2Shiba, Gastroenterology, Tel Hashomer, Israel

P473

Antibodies to infliximab, body weight and low serum albumin levels increase clearance of infliximab, a population pharmacokinetic study in 324 IBD patients

Authors:

J.F. Brandse*1, D.R. Mould2, Y.K. Ashruf1, O.S. Smeekes1, M. Löwenberg1, C.Y. Ponsioen1, G.R. van den Brink1, G.R. D'Haens1

1Academic Medical Center, Inflammatory Bowel Disease Center, Amsterdam, Netherlands, 2Projections Research Inc, Projections Research Inc, Phoenixville, United States